Taiwan · Delayed Price · Currency is TWD MARX Biotech Statistics
Total Valuation
MARX Biotech has a market cap or net worth of TWD 2.38 billion. The enterprise value is 2.52 billion.
| Market Cap | 2.38B |
| Enterprise Value | 2.52B |
Important Dates
The next estimated earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MARX Biotech has 521.98 million shares outstanding. The number of shares has increased by 4.77% in one year.
| Current Share Class | 521.98M |
| Shares Outstanding | 521.98M |
| Shares Change (YoY) | +4.77% |
| Shares Change (QoQ) | +6.43% |
| Owned by Insiders (%) | 22.50% |
| Owned by Institutions (%) | n/a |
| Float | 352.91M |
Valuation Ratios
The trailing PE ratio is 82.03.
| PE Ratio | 82.03 |
| Forward PE | n/a |
| PS Ratio | 4.06 |
| PB Ratio | 8.23 |
| P/TBV Ratio | 10.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 78.78 |
| EV / Sales | 4.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.67 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.53 |
| Interest Coverage | -13.80 |
Financial Efficiency
Return on equity (ROE) is 12.45% and return on invested capital (ROIC) is -16.44%.
| Return on Equity (ROE) | 12.45% |
| Return on Assets (ROA) | -13.57% |
| Return on Invested Capital (ROIC) | -16.44% |
| Return on Capital Employed (ROCE) | -34.78% |
| Weighted Average Cost of Capital (WACC) | 7.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 80 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, MARX Biotech has paid 17.24 million in taxes.
| Income Tax | 17.24M |
| Effective Tax Rate | 35.54% |
Stock Price Statistics
The stock price has decreased by -11.74% in the last 52 weeks. The beta is 0.71, so MARX Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -11.74% |
| 50-Day Moving Average | 5.09 |
| 200-Day Moving Average | 5.31 |
| Relative Strength Index (RSI) | 34.69 |
| Average Volume (20 Days) | 988,462 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MARX Biotech had revenue of TWD 584.74 million and earned 32.01 million in profits. Earnings per share was 0.06.
| Revenue | 584.74M |
| Gross Profit | 296.99M |
| Operating Income | -152.74M |
| Pretax Income | 48.51M |
| Net Income | 32.01M |
| EBITDA | -144.18M |
| EBIT | -152.74M |
| Earnings Per Share (EPS) | 0.06 |
Balance Sheet
The company has 73.31 million in cash and 219.99 million in debt, with a net cash position of -146.68 million or -0.28 per share.
| Cash & Cash Equivalents | 73.31M |
| Total Debt | 219.99M |
| Net Cash | -146.68M |
| Net Cash Per Share | -0.28 |
| Equity (Book Value) | 288.60M |
| Book Value Per Share | 0.53 |
| Working Capital | 156.36M |
Cash Flow
In the last 12 months, operating cash flow was -140.53 million and capital expenditures -3.59 million, giving a free cash flow of -144.12 million.
| Operating Cash Flow | -140.53M |
| Capital Expenditures | -3.59M |
| Depreciation & Amortization | 14.00M |
| Net Borrowing | 33.70M |
| Free Cash Flow | -144.12M |
| FCF Per Share | -0.28 |
Margins
Gross margin is 50.79%, with operating and profit margins of -26.12% and 5.47%.
| Gross Margin | 50.79% |
| Operating Margin | -26.12% |
| Pretax Margin | 8.30% |
| Profit Margin | 5.47% |
| EBITDA Margin | -24.66% |
| EBIT Margin | -26.12% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.23%.
| Dividend Per Share | 0.06 |
| Dividend Yield | 1.23% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.77% |
| Shareholder Yield | -3.54% |
| Earnings Yield | 1.35% |
| FCF Yield | -6.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 11, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Jul 11, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |